COMMERCIALLY FOCUSED INNOVATIVE MEDICINES
Further add-on acquisitions and licensing to strengthen hospital perioperative space.
Existing product portfolio
Refocol (propofol)®
• Recofol N – propofol with MCT/LCT formulation.
• Recofol EDTA – propofol plus EDTA.
• Propofo VET – propofol for animals.
More about Recofol
OZALIN / OZASED®* (2mg/ml oral midazolam solution)
• ADV6209 was the former name of the product.
More about Ozalin/Ozased
OGNA® Dental Portfolio
• Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel).
• Endodontic Medical Devices (CE marked).
Discover our products
Strategic growth pillars
Primex
- Expand commercialisation of Ozalin/Ozased geographically
- Grow global penetration of Recofol® into new private and public channels
- Pursue bolt-on and transformational acquisitions and product / portfolio licensing deals to strengthen and scale our perioperative footprint
- Extend our perioperative and paediatric product portfolio to new indications and via new formulations
Ogna
- Leverage strong brand awareness and high quality product portfolio to expand geographically
- Pursue product / portfolio in-licensing deals for Italy, leveraging Ogna’s strong commercial network
- Pursue bolt-on and transformational product and corporate acquisitions to enhance our endodontics market leadership
